Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept

Scandinavian Journal of Rheumatology

Volumn 38, Issue 4, 2009, Pages 311-316

  Bourrtessier, J ^a   Fortin, C ^a   Belisle, A ^a   Desmarais, E ^a   Choquette, D ^a   Sencal, J L ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; ETANERCEPT; INFLIXIMAB; ITRACONAZOLE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CULTURE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; CRYPTOCOCCUS NEOFORMANS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANNICULITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

AGED; ANTI-BACTERIAL AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FUNGEMIA; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; MALE; MYOSITIS; OPPORTUNISTIC INFECTIONS; PANNICULITIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT;

EID: 70350630258     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740902776935     Document Type: Article

References (21)

1. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis D. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008;83:181-194
2. Tran TA, DuPree M, Carlson JA. Neutrophilic lobular (pustular) panniculitis associated with rheumatoid arthritis: A case report and review of the literature. Am J Dermatopathol 1999;21:247-252
3. Rivest C, Miller FW, Love L, Turgeon PP, Blier C, Senécal JL. Focal myositis presenting as neck pseudothrombophlebitis in mixed connective tissue disease. Arthritis Rheum 1996;39: 1254-1258
4. Chevalier X, Larget-Piet B, Gherardi R. Proliferative myositis as a complication of rheumatoid vasculitis. J Rheumatol 1993;20:1259-1260
5. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007;86:242-251
6. Sawalha AH, Lutz BD, Chaudhary NA, Kern WK, Harley JB, Greenfield RA. Panniculitis: A presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol 2003;9:259-262
7. Voloshin DK, Lacomis D, McMahon D. Disseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositis. Muscle Nerve 1995;18:531-535
8. Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2008;5:283-287
9. Yan TD, Kavuru MS, Yen-Lieberman B, Brzezinski A, Gordon SM. Immune function evaluation (ImmuKnow Assay) in a patient treated with infliximab who developed miliary histoplasmosis. Infect Dis Clin Pract 2005;13:315-317
10. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
11. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Resp Crit Care Med 2003;167:1279-1282
12. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78-79
13. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-626
14. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-324
15. Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. In:, 40th Annual Meeting of the Infectious Diseases Society of America. 24-27 October 2002, Chicago, IL. Abstract 378.
16. Deepe GS, Bullock WE. Histoplasmosis: A granulomatous inflammatory response. In Gallin JI, Goldstein IM, Synderman R, editors. Inflammation: basic principles and clinical correlates. 2nd edn, New York: Raven Press, 1995: 943-958
17. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-2570
18. Maha AA, Mohamad SS, Larry MB, Glenn DR, Randall CW. Systemic histoplasmosis a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007;86:162-169
19. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 2008;21:421-425
20. Wallis RS, Broder MS, Wong JY, Beenhouwer DO. Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004;39:1254-1255
21. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-894